Product Description:

• ARIXTRA 2.5 mg/0.5 ml Pack is 10  pre-filled, single-dose and single-use syringe for SC injection for prevention of VTE Prophylaxis.

How To Use:

• SC / OD for 14 or 21 days after abdominal, Bariatric & Plastic surgeries.

Prevention after major orthopedic interventions or abdominal surgery:

• The recommended dose is 2.5 mg once daily postoperatively as SC injection. 


• The initial dose should be given 6 hours after the end of the surgical procedure, provided that hemostasis has been established. 


• Treatment should continue until the risk of VTE is reduced, usually, until the patient is ambulatory, at least 5-9 days after the procedure. 


• In hip fracture surgery, the patient has an increased risk of VTE beyond 9 days after the procedure, and extended prophylaxis for up to a further 24 days should be considered.

Prevention at high risk of thromboembolic complications based on individual risk assessment:

• The recommended dose is 2.5 mg once daily as SC injection.


• A treatment length of 6-14 days has been used in clinical studies.

Treatment of superficial vein thrombosis:

• The recommended dose is 2.5 mg once daily as SC injection.


• Indicated for acute, symptomatic, isolated, spontaneous, superficial  venous thrombosis of the lower extremities, which is at least 5 cm long and documented by ultrasonographic examination or other suitable methods. 


• Treatment should be initiated as soon as possible after diagnosis and after exclusion of concomitant  DVT or superficial vein thrombosis within 3 cm of the point where the saphenous vein meets the femoral vein.


• Treatment should continue for a minimum of 30 days and a maximum of 45 days at high risk of thromboembolic complications. 


• The patient can inject the preparation themselves after careful instructions from a doctor, see package insert.


• Fondaparinux treatment should be discontinued 24 hours before surgery or other invasive procedures, if possible. 


• The treatment can be resumed at least 6 hours postoperatively if hemostasis has been achieved.

Caution & Warnings:

• ARIXTRA can be used with cautious in patients with GFR of 30-50 ml / min. (20-50 ml/min in ACS indication).


• ARIXTRA is contraindicated in patients with GFR < 30 ml / min. (20 ml/min is ACS indication).

Ingredients:

• Fondaparinux Sodium.

Product Details:

• Brand: ARIXTRA
• Product Form: pre-filled subcutaneous injection
• Product Type: Syringes